Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Cancer - 1 Aug 2017

Nicolini Franck E, Basak Grzegorz W, Kim Dong-Wook, Olavarria Eduardo, Pinilla-Ibarz Javier, Apperley Jane F, Hughes Timothy, Niederwieser Dietger, Mauro Michael J, Chuah Charles, Hochhaus Andreas, Martinelli Giovanni, DerSarkissian Maral, Duh Mei Sheng, McGarry Lisa J, Kantarjian Hagop M, Cortes Jorge E

Abstract excerpt

BACKGROUND: Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blast Crisis
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Philadelphia Chromosome

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Pyridazines

Share to Stem Cell Transplantation

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 28387926
DOI: 10.1002/cncr.30558
PMCID: PMC5573914

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.PMID 28387926Read ↗

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasSemantic proximity Read ↗

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialSemantic proximity Read ↗

Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.Semantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registrySemantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registrySemantic proximity Read ↗

Ponatinib in refractory Philadelphia chromosome-positive leukemias.Semantic proximity Read ↗

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.Semantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialSemantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular ManagementSemantic proximity Read ↗

Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity Read ↗

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.